Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Terence M. Davidson, MD is conducting a research study to find out more about the topical
application of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis
(nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).